Entrada Therapeutics, Inc. (TRDA) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	4.7M	25.4M	210.8M	129.0M	—
Cost of Revenue	40.1M	4.1M	—	—	—
Gross Profit	(35.4M)	21.3M	210.8M	129.0M	—
Operating Expenses
R&D Expense	140.7M	142.3M	125.3M	99.9M	66.6M
SG&A Expense	40.5M	41.0M	38.5M	32.3M	30.6M
General & Admin Expense	40.5M	41.0M	38.5M	32.3M	30.6M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(40.1M)	(6.0M)	—	—	—
Total Operating Expenses	141.2M	177.3M	163.8M	132.2M	97.2M
Cost and Expenses	181.2M	181.4M	163.8M	132.2M	97.2M
Operating Income (EBIT)	(176.5M)	(156.0M)	47.0M	(3.2M)	(97.2M)
Non-Operating
Interest Income	11.6M	—	19.5M	15.2M	2.6M
Interest Expense	—	—	—	—	2.6M
Net Interest Income	11.6M	—	19.5M	15.2M	—
Other Non-Op Income/Expense	11.6M	13.2M	19.5M	15.2M	2.6M
Non-Operating Income (excl Interest)	(11.6M)	(13.2M)	(19.5M)	(15.2M)	(5.3M)
EBT (Pre-Tax Income)	(165.0M)	(142.8M)	66.5M	12.1M	(94.6M)
Income Tax Expense	819.0K	924.0K	859.0K	18.7M	—
Bottom Line
Net Income	(165.8M)	(143.8M)	65.6M	(6.7M)	(94.6M)
Earnings from Cont. Ops	(165.8M)	(143.8M)	65.6M	(6.7M)	(94.6M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(165.8M)	(143.8M)	65.6M	(6.7M)	(94.6M)
Per Share
Basic EPS	($3.97)	($3.47)	$1.76	($0.20)	($2.79)
Diluted EPS	($3.97)	($3.47)	$1.68	($0.20)	($2.79)
Revenue Per Share	$0.11	$0.61	$5.65	$3.90	$0.00
Shares
Basic Shares Outstanding	42.2M	41.4M	37.3M	33.1M	31.3M
Diluted Shares Outstanding	42.2M	41.4M	39.0M	33.1M	31.3M
Profitability Metrics
EBITDA	(164.9M)	(138.7M)	70.3M	14.9M	(90.1M)
D&A	91.0K	4.1M	3.8M	2.8M	1.9M
EBIT	(165.0M)	(142.8M)	66.5M	12.1M	(92.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026